Candidate markers for the detection of hepatocellular carcinoma in low-molecular weight fraction of serum

Carcinogenesis

Volumn 28, Issue 10, 2007, Pages 2149-2153

  Goldman, Radoslav ^a   Ressom, Habtom W ^a   Abdel Hamid, Mohamed ^b   Goldman, Lenka ^a   Wang, Antai ^a   Varghese, Rency S ^a   An, Yanming ^a   Loffredo, Christopher A ^a   Drake, Steven K ^c   Eissa, Sohair A ^d   Gouda, Iman ^d   Ezzat, Sameera ^e   Moiseiwitsch, Francoise Seillier ^a  

^a GEORGETOWN UNIVERSITY   (United States)

^b MINIA UNIVERSITY   (Egypt)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d NATIONAL CANCER INSTITUTE   (Egypt)

^e MENOUFIA UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIGEN; VIRUS RNA;

ACCURACY; ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CYTOLOGY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE MARKER; ECHOGRAPHY; EGYPT; ENZYME IMMUNOASSAY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOLECULAR WEIGHT; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS; TANDEM MASS SPECTROMETRY;

ADOLESCENT; ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; EGYPT; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MOLECULAR WEIGHT; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 35148834673     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgm177     Document Type: Article

References (35)

1. Montalto,G. et al.(2003) Epidemiology, risk factors, and natural history of hepatocellular carcinoma. Ann. N. Y. Acad. Sci., 963 13-20.
2. Parkin D.M. (2006) The global health burden of infection-associated cancers in the year 2002. Int. J. Cancer, 118, 3030-3044.
3. Mizokami,M. et al. (2005) Tracing the evolution of hepatitis C virus in the United States, Japan, and Egypt by using the molecular clock. Clin. Gastroenterol. Hepatol., 3, S82-S85.
4. Deuffic-Burban,S. et al. (2006) Expected increage in hepatitis C-related mortality in Egypt due to pre-2000 infections. J. Hepatol. 44, 455-461.
5. Ezzat,S. et al. (2005) Associations of pesticides, HCV, HBV, and hepato-cellular carcinoma in Egypt. Int. J. Hyg. Environ. Health, 208, 329-339.
6. Perz,J.F. et al. (2006) The coming wave of HCV-related liver disease: Dilemmas and challenges. J. Hepatol., 44, 441-443.
7. Hassan,M.M. et al. (2001) The role of hepatitis C in hepatocellular carcinoma: A case control study among Egyptian patients. J. Clin. Gastroenterol., 33, 123-126.
8. El-Serag,H.B. et al. (1999) Rising incidence of hepatocellular carcinoma in the United States. N. Engl. J. Med., 340, 745-750.
9. Wong, J.B. et al. (2000) Estimating future hepatitis C morbidity, mortality, and costs in the United States, Am. J. Public Health, 90, 1562-1569.
10. Di Bisceglie,A. M. et al. (2003) Hepatitis C-related hepatoceflular carcinoma in the United States: Influence ethnic status. Am. J. Gastroenterol., 98, 2060-2063.
11. Ikeda,K. et al. (1998) Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: A prospective observation of 2215 patients. J. Hepatol., 28, 930-938.
12. Llovet,J.M. (2005) Updated treatment approach to hepatocellular carcinoma. J. Gastroenterol., 40, 225-235.
13. Schwartz,J.M. et al. (2003) Treatment bf hepatocellular carcinoma. Curr. Treat. Options Gastroenterol., 6, 465-472.
14. Steel,L.F.et al. (2001) A proteomic approach for the discovery of early detection markers of hepatocellular carcinoma. Dis. Markers, 17, 179-189.
15. Lopez,L. J. et al. (2004) Hepatocellular carcinoma. Curr. Opin. Gastroenterol., 20, 248-253.
16. Marrero,J.A. (2006) Screening tests for. hepatocellular carcinoma. Clin. Liver Dis., 9, 235-251.
17. Gupta,S. et al. (2003) test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C, A systematic review and critical analysis. Ann. Intera. Med., 139 46-50.
18. Filmus,J. et al. (2004) Glypican-3 and alphafetoprotein as diagnostic tests for hepatocellular carcinoma. Mol. Diagn., 8 207-212.
19. Block,T.M. et al. (2005) Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans. Proc. Natl Acad. Sci. USA, 102, 779-784.
20. Chignard,N. et al. (2006) Cleavage of endoplasmic reticulum proteins in hepatocellular carcinoma: Detection of generated fragments in patient sera. Gastroenterology, 130, 2010-2022.
21. Lee,I.N. et al. (2006) Identification of complement C3a as a candidate biomarker in human chronic hepatitis C and HCV-related hepatocellular carcinoma using a proteomics approach. Proteomics, 6, 2865-2873.
22. Villanueva J. et al. (2006) Differential exoprotease activities confer tumor-specific serum peptidome patterns. J. Clin. Invest., 116, 271-284.
23. Tammen,H. et al. (2005) Peptidomic analysis of human blood specimens: Comparison between plasma specimens and serum by differential peptide display. Proteomics, 5, 3414-3422.
24. Hortin,G.L. et al. (2006) Proteomics: A new diagnostic frontier. Clin. Chem., 52, 1218-1222.
25. Orvisky,E. et al. (2006) Enrichment of low molecular weight fraction of serum for mass spectrometric analysis of peptides associated with hepatocellular carcinoma. Proteomics, 6, 2895-2902.
26. Ressom,H. et al. (2005) Analysis of MALDI-TOF serum profiles for biomarker selection and sample classification. Proceedings of the IEEE Symposium on Computational Inteligence in Bioinformatics and Computational Biology. La Jolla, CA, 378-384.
27. Abdel-Hamid,M. et al. (1997) Optimization, assessment, and proposed use of a direct nested reverse transcription-polymerase chain reaction protocol for the detection of hepatitis C virus. J. Hum. Virol., 1, 58-65.
28. Tirumalai,R.S. et al. (2003) Characterization of the low molecular weight human serum proteome. Mol. Cell. Proteomics, 2, 1096-1103.
29. Ressom,H. et al. (2005) Analysis of mass spectral serum profiles for biomarker selection. Bioinformatics, 21, 4039-4045.
30. Zhang,B.H. et al. (2004) Randomized controlled trial of screening for hepatocellular carcinoma. J. Cancer Res. Clin. Oncol., 130 417-422.
31. Schulz-Knappe,P. et al. (2005) The peptidomics. concept. Comb. Chem. High Throughput Screen., 8, 697-704.
32. Hortin,G.L. (2006) The MALDI-TOF mass spectrometric view of the plasma proteome and peptidome. Clin. Chem., 52, 1223-1237.
33. Ransohoff,D.F. (2005) Bias as a threat to the validity of cancer molecular-marker research. Nat. Rev. Cancer, 5, 142-149.
34. Ransohoff,D.F. (2004) Rules of evidence for cancer molecular-marker discovery and validation. Nat. Rev. Cancer, 4, 309-314.
35. Villanueva,J. et al. (2005) Correcting common errors in identifying cancer-specific peptide signatures. J. Proteome Res., 4, 1060-1072.